From diabetes.co.uk/news
Central body fat “contributes to psoriasis” more than total body fat, latest evidence has claimed.
A new study has found that women with increased belly fat are at greater risk of developing psoriasis compared to men with increased abdominal fat.
Psoriasis is a skin condition that causes flaky patches of skin, which form silvery-white or grey scales.
In the trial, the team of researchers examined the health data of 330,000 people, 9,000 of whom are living with psoriasis.
Using both traditional methods and advanced imaging techniques, the scientists analysed 25 different measures of body fat to see how they are linked with psoriasis.
First author Dr Ravi Ramessur said: “Our research shows that where fat is stored in the body matters when it comes to psoriasis risk.
“Central fat – especially around the waist – seems to play a key role. This has important implications for how we identify individuals who may be more likely to develop psoriasis or experience more severe disease, and how we approach prevention and treatment strategies.”
Corresponding author Dr Catherine H Smith said: “As rates of obesity continue to rise globally, understanding how different patterns of body fat influence chronic inflammatory conditions such as psoriasis is important.
“Our findings suggest that central body contributes to psoriasis risk irrespective of genetic predisposition and reinforces the importance of measuring waist circumference and pro-active healthy weight strategies in psoriasis care.”
Dr Ramessur explained: “We were surprised by how consistently strong the association was across different central fat measures and how much stronger the effect was in women.
“The observed links between central body fat and psoriasis suggest that there may be underlying biological mechanisms contributing to the disease that are not yet fully understood and which warrant further investigation.”
Dr Joel M Gelfand commented: “The strong relationship between psoriasis and obesity and the emerging promise of glucagon-like peptide-1 receptor agonists (GLP1RA) for reducing psoriasis morbidity is a call to action for large scale clinical trials of GLP1RA monotherapy for treatment of psoriasis.
“Our current paradigm of just focusing on the skin and joint manifestations when treating psoriasis is outdated in the context of our evolving understanding of the right relationship of psoriasis is outdated in the context of our evolving understanding of the tight relationship of psoriasis, obesity and cardiometabolic disease.”
Read the study in the Journal of Investigative Dermatology.
No comments:
Post a Comment